Modified bordetella pertussis strain and application thereof

By genetic modification of the pertussis Bauterus strain, knocking out or making the BP2992, pldA and mlaF genes not expressed or inactive, and combined with ultrasound treatment, the problem of low OMV yield was solved, and the OMV secretion was significantly increased, providing technical support for the development of pertussis OMV vaccine.

CN120118819AActive Publication Date: 2025-06-10SHANGHAI YUGUAN BIOTECH CO LTD

Patent Information

Application Number
CN202510621870.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-05-15
Publication Date
2025-06-10
Estimated Expiration
2045-05-15

AI Technical Summary

Technical Problem

The natural secretion yield of pertussis OMV is extremely low, which limits the research and industrial production of pertussis OMV. The existing production increase method is not effective.

Method used

By genetic modification of the pertussis strain, knocking out or inactive BP2992, pldA and mlaF genes are not expressed or expressed, and combined with ultrasound treatment, the secretion of OMV is promoted.

Benefits of technology

It significantly increased the secretion of pertussis OMV, making its output dozens of times, laying a good technical foundation for the development of pertussis OMV vaccine.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN120118819A_ABST
    Figure CN120118819A_ABST
Patent Text Reader

Abstract

The invention discloses a modified bordetella pertussis strain and an application thereof. The modified Bordetella pertussis strain is characterized in that in the Bordetella pertussis strain BAA-589, the BP2992 protein is not expressed, or the inactive BP2992 protein is expressed, the pldA protein is not expressed, or the inactive pldA protein is expressed, and the mla F protein is not expressed, or the inactive mla F protein is expressed. When the Bordetella pertussis strain is treated by combining an ultrasonic method, compared with wild Bordetella pertussis BAA-589, the Bordetella pertussis strain has a remarkable high-foaming phenotype, the OMV secretion amount is remarkably increased, and a good technical foundation is laid for developing a Bordetella pertussis OMV vaccine.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of bioengineering, and particularly to a modified Bordetella pertussis strain and its application. Background Art

[0002] There are various means to increase the production of bacterial outer membrane vesicles (OMVs), which can be divided into two major categories: increasing the production from the strain aspect and increasing the production from the OMV production process aspect.

[0003] Starting from the strain aspect, the production can be increased by editing genes related to the OMV secretion process. There are 3 common strategies. The first strategy is to weaken the binding between the outer membrane and the peptidoglycan layer, making the outer membrane loose and easy to form vesicles for secretion. Outer membrane lipoproteins are the key bridges for the binding between the outer membrane and peptidoglycan. Reducing the content of outer membrane lipoproteins is an important means to reduce the binding between the outer membrane and the peptidoglycan layer. The second strategy is to increase the phospholipid content on the outer membrane to increase the outer membrane curvature. The third strategy is to increase the internal pressure in the periplasmic space to promote OMV secretion.

[0004] Starting from the OMV production process aspect, the secretion amount of OMV can be increased by various induction methods. However, compared with OMV obtained by natural secretion, each induction method has its own deficiencies; detergents can also be used to induce OMV secretion, but the formed OMV will lose LPS with adjuvant effect and lipoproteins that may have immunogenicity; reagents such as EDTA can also be used to induce OMV secretion, but it may reduce the stability of the OMV membrane; heat induction can also be used to induce OMV secretion, but the heating method may change the phospholipid composition of the OMV membrane; there is also the use of ultrasonic induction to secrete OMV, but the OMV secretion amount is often not satisfactory.

[0005] The yield of OMVs naturally secreted by wild-type Bordetella pertussis strains is extremely low, severely limiting the research and industrial production of Bordetella pertussis OMVs. Currently, there are limited reports on increasing the production of Bordetella pertussis OMVs, and the reported yield increase effects are not satisfactory. For example, Eline F. de Jonge et al. started from the strain level and knocked out the phospholipid-related proteins pldA and malF of Bordetella pertussis, and found that it could improve the natural secretion yield of Bordetella pertussis OMVs to a certain extent. Compared with the wild type, the double knockout of pldA and malF genes increased by about 4 times (Current Research in Microbial Sciences, Volume 3, 2022, 100172, ISSN 2666-5174). D Hozbor et al. started from the OMV production process and found that the use of ultrasonic induction process could also increase the yield of Bordetella pertussis OMVs within a certain limit (Hozbor, D., Rodriguez, M., Fernández, J. et al. Release of Outer Membrane Vesicles from Bordetella pertussis. Curr Microbiol 38, 273–278 (1999).).

[0006] In summary, to develop Bordetella pertussis OMV vaccines, there is an urgent need to develop methods for increasing the production of Bordetella pertussis OMVs. Summary of the Invention

[0007] To solve the above technical problems, the present invention provides a modified Bordetella pertussis strain and its application.

[0008] Specifically, the present invention provides a modified Bordetella pertussis strain, which does not express the BP2992 protein or expresses an inactive BP2992 protein compared with the Bordetella pertussis strain BAA-589.

[0009] In some embodiments, the Bordetella pertussis strain contains a BP2992 gene mutation, which results in the non-expression of the BP2992 protein or the expression of an inactive BP2992 protein.

[0010] In some specific embodiments, the BP2992 gene mutation includes a deletion of the BP2992 gene.

[0011] In some specific embodiments, the BP2992 gene encodes the amino acid sequence shown in SEQ ID NO: 7 or its nucleotide sequence is as shown in SEQ ID NO: 6.

[0012] In some embodiments, in the Bordetella pertussis strain, the pldA protein and / or the mlaF protein is not expressed; or,

[0013] an inactive pldA protein and / or an inactive mlaF protein is expressed.

[0014] In some embodiments, the Bordetella pertussis strain is one in which in Bordetella pertussis strain BAA-589, the BP2992 protein is not expressed or an inactive BP2992 protein is expressed, the pldA protein is not expressed or an inactive pldA protein is expressed, and the mlaF protein is not expressed or an inactive mlaF protein is expressed.

[0015] In some embodiments, the Bordetella pertussis strain comprises mutations in the BP2992, pldA, and mlaF genes; or, the Bordetella pertussis strain comprises mutations in the BP2992 and pldA genes; or, the Bordetella pertussis strain comprises mutations in the BP2992 and mlaF genes.

[0016] In some specific embodiments, the pldA gene mutation comprises a deletion of the pldA gene; and / or, the mlaF gene mutation comprises a deletion of the mlaF gene.

[0017] In some specific embodiments, the pldA gene encodes the amino acid sequence shown in SEQ ID NO: 11 or its nucleotide sequence is as shown in SEQ ID NO: 10; and / or, the mlaF gene encodes the amino acid sequence shown in SEQ ID NO: 15 or its nucleotide sequence is as shown in SEQ ID NO: 14.

[0018] In some specific embodiments, the Bordetella pertussis contains deletion mutations of the BP2992 gene, the pldA gene, and the mlaF gene.

[0019] The present invention also provides a method for generating a modified Bordetella pertussis strain, the method comprising:

[0020] introducing a mutation into the BP2992 gene in a Bordetella pertussis strain, thereby obtaining a modified Bordetella pertussis strain with a BP2992 gene mutation, and thereby resulting in non-expression of the BP2992 protein or expression of an inactive BP2992 protein.

[0021] In some specific embodiments, the method comprises:

[0022] Introduce mutations into the BP2992 gene, pldA gene, and mlaF gene in a Bordetella pertussis strain to obtain a modified Bordetella pertussis strain in which the BP2992 gene, pldA gene, and mlaF gene are all mutated; or,

[0023] Introduce mutations into the BP2992 gene and pldA gene in a Bordetella pertussis strain to obtain a modified Bordetella pertussis strain in which the BP2992 gene and pldA gene are both mutated; or,

[0024] Introduce mutations into the BP2992 gene and mlaF gene in a Bordetella pertussis strain to obtain a modified Bordetella pertussis strain in which the BP2992 gene and mlaF gene are both mutated;

[0025] Wherein, the Bordetella pertussis strain is Bordetella pertussis BAA-589.

[0026] The present invention also provides a method for preparing Bordetella pertussis outer membrane vesicles, the method comprising sonicating the Bordetella pertussis strain according to any one of the present disclosure.

[0027] In some embodiments, the sonication does not lyse the cells of the Bordetella pertussis strain and promotes the secretion of Bordetella pertussis outer membrane vesicles by the cells.

[0028] In some embodiments, the method comprises the following steps:

[0029] a) Culturing the Bordetella pertussis strain according to any one of the present disclosure;

[0030] b) Sonicating the strain obtained in step a) to produce Bordetella pertussis outer membrane vesicles.

[0031] In some embodiments, for a bacterial solution with a concentration of 20-40 OD / 10 ml, the sonication conditions are selected from one or more of the following:

[0032] (1) The sonication power is 65-90 W;

[0033] (2) The total sonication time is 3-7 min;

[0034] (3) The pulse mode is intermittent pulse, the on-cycle time is 3-5 s, and the off-cycle time is 5-10 s.

[0035] In some embodiments, the sonication conditions are selected from one or more of the following:

[0036] (1) The sonication power is 75%-85%;

[0037] (2) The total ultrasonic time is 3 - 7 min;

[0038] (3) The pulse mode is intermittent pulse, the on - cycle time is 3 - 5 s, and the off - cycle time is 5 - 10 s.

[0039] In some specific embodiments, the conditions for the ultrasonic treatment are:

[0040] (1) The ultrasonic power is 84.5 W;

[0041] (2) The total ultrasonic time is 5 min;

[0042] (3) The pulse mode is intermittent pulse, the on - cycle time is 5 s, and the off - cycle time is 5 s.

[0043] The present invention also provides the use of the Bordetella pertussis strain described in any one of the present disclosures.

[0044] In some specific embodiments, the use is for the preparation of Bordetella pertussis outer membrane vesicles.

[0045] The present invention also provides Bordetella pertussis outer membrane vesicles prepared by the method described in any one of the present disclosures.

[0046] The present invention also provides a composition comprising at least two of the following:

[0047] (1) The Bordetella pertussis strain described in any one of the present disclosures;

[0048] (2) The Bordetella pertussis outer membrane vesicles described in the present disclosure;

[0049] (3) An adjuvant and / or a pharmaceutically acceptable carrier.

[0050] The present invention also provides the use of the Bordetella pertussis strain described in the present disclosure, the Bordetella pertussis outer membrane vesicles described in the present disclosure, or the composition described in the present disclosure in the preparation of a drug or vaccine for preventing and / or treating Bordetella pertussis infection.

[0051] On the basis of conforming to common general knowledge in the art, the above - mentioned preferred conditions can be combined arbitrarily to obtain various preferred examples of the present invention.

[0052] The reagents and raw materials used in the present invention are all commercially available.

[0053] The positive and progressive effects of the present invention are as follows:

[0054] The present invention provides a new Bordetella pertussis strain with non-expression of pldA, mlaF, and BP2992 genes. When processed in combination with ultrasound, this strain has a significantly higher foaming phenotype compared to the wild-type Bordetella pertussis BAA-589, and the OMV secretion amount is significantly increased, laying a good technical foundation for the development of pertussis OMV vaccine. Brief Description of the Drawings

[0055] Figure 1 It is a map of the homologous recombination backbone plasmid.

[0056] Figure 2 It is a comparison of the sequencing results of the BAA-589ΔBP2992 strain.

[0057] Figure 3 It is a comparison of the sequencing results of the BAA-589ΔBP2992ΔpldA strain.

[0058] Figure 4 It is a comparison of the sequencing results of the BAA-589ΔBP2992ΔpldAΔmlaF knockout strain.

[0059] Figure 5 It is a comparison of the OD concentrations of the BAA-589ΔBP2992ΔpldAΔmlaF strain and the wild-type strain BAA-589 after 24 hours of culture.

[0060] Figure 6 It is a comparison of the OMV protein concentrations of the BAA-589ΔBP2992ΔpldAΔmlaF strain and the wild-type strain BAA-589.

[0061] Figure 7 It is a comparison of the sOMV particle concentrations of the BAA-589ΔBP2992ΔpldAΔmlaF strain and the wild-type strain BAA-589.

[0062] Figure 8 It is a particle size distribution map of sOMV of the BAA-589ΔBP2992ΔpldAΔmlaF strain and the wild-type strain BAA-589.

[0063] Figure 9 It is a comparison of the OD concentrations of the BAA-589ΔpldAΔmlaF strain and the wild-type strain BAA-589 after 24 hours of culture.

[0064] Figure 10 It is a comparison of the OMV protein concentrations of the BAA-589ΔpldAΔmlaF strain and the wild-type strain BAA-589.

[0065] Figure 11Comparison of sOMV particle concentrations between the BAA - 589ΔpldAΔmlaF strain and the wild - type strain BAA - 589.

[0066] Figure 12 Particle size distribution diagram of sOMV of the BAA - 589ΔpldAΔmlaF strain and the wild - type strain BAA - 589. Detailed implementation manners

[0067] To better understand the present invention, some terms are first defined. Other definitions are listed throughout the detailed implementation manners section.

[0068] The term "non - expressing protein" or "expressing an inactive protein" refers to a decrease in protein expression / non - expression or a decrease in the activity of the expressed protein / inactivity caused by means such as "gene mutation" or "gene silencing". Among them, "gene silencing" refers to the use of molecular biology techniques to inhibit or block the expression of specific genes in a strain, making it unable to generate functional protein or nucleic acid products. It does not involve changes in gene structure and is mainly achieved through epigenetic regulation or RNA interference and other pathways.

[0069] The term "BP2992 gene" is a gene in Bordetella pertussis that encodes the BP2992 protein; currently, the scientific community does not know the function of this protein, but the present invention discovers that one of its functions is to affect the secretion amount of outer membrane vesicles. Therefore, in this disclosure, expressing "inactive BP2992 protein" can increase the secretion amount of outer membrane vesicles of Bordetella pertussis under ultrasonic conditions.

[0070] The term "pldA gene" encodes the pldA protein, which is a phospholipase, and its phospholipase activity can degrade phospholipids on the outer membrane and release fatty acids.

[0071] The term "mlaF gene" encodes the mlaF protein, an ATPase that provides energy for the Mla system, and is one of the most conserved proteins in the Mla system.

[0072] The term "ultrasound" refers to the use of the physical effects generated by the high - frequency mechanical vibration of ultrasonic waves to act on the target object. In the present invention, it refers to generating ultrasonic waves through an ultrasonic cell disruptor to act on bacteria, controlling parameters such as ultrasonic time, power, working / interval cycle, etc., to promote the secretion of outer membrane vesicles by bacteria.

[0073] The present invention will be further described below by way of examples, but the present invention is not limited to the scope of the described examples. For the experimental methods without specific conditions indicated in the following examples, they are carried out according to conventional methods and conditions, or selected according to the product specifications. In order to exemplarily illustrate the technical solutions and technical effects of the present invention, the present invention selects the BAA-589 strain purchased from ATCC (American type culture collection).

[0074] Example 1: Method for modifying Bordetella pertussis gene by homologous recombination

[0075] 1.1 Construction of exogenous DNA donor plasmid

[0076] The exogenous backbone plasmid contains ori-ColE1 / pMB1 / pBR322 / pUC, the mobilization element OriT and traJ, the gentamicin resistance gene (Gen) and the galk counter-selection gene. The sequence of the exogenous backbone plasmid is shown in SEQ ID NO: 1 (the structure of the backbone plasmid is as shown in Figure 1 ), in which, the sequence of the gentamicin resistance gene is shown in SEQ ID NO: 2, and the sequence of the galk counter-selection gene is shown in SEQ ID NO: 3. The upstream and downstream homologous arms of the target gene integration site are inserted between site-up (sequence shown in SEQ ID NO: 4) and site-down (sequence shown in SEQ ID NO: 5) upstream of the insertion site of the exogenous backbone plasmid, so as to obtain the exogenous DNA donor plasmid.

[0077] 1.2 Electroporation of the donor plasmid

[0078] Activate the glycerol bacteria on the BG plate (Bordet-Gengo solid plate) and culture them at 37 °C until colonies grow. Inoculate the colonies into the SS liquid culture (Stainer-Scholte liquid medium) for enlarged culture.

[0079] Wash repeatedly with about 10% glycerol buffer at about 4 °C to prepare the electrocompetent cells of the strain, and perform electrotransformation on an electroporator (BTX, ECM630). The electrotransformation parameters are set as follows: 1.6 - 2.2 kV, 200 Ω, 25 μF, and the electrotransformation time does not exceed 5 ms. Immediately after electroporation, add SS liquid medium for resuscitation. Transfer the system to a sterile EP tube and culture it on a shaker at 35 - 37 °C and 220 - 240 rpm for resuscitation. After resuscitation, centrifuge to discard the supernatant, add SS liquid medium, resuspend the cells, and spread them on a BG solid plate containing 10 μg / mL gentamicin resistance (BG-G). The plate is placed in an environment of 35 - 37 °C for culture, and the single clones that grow are the possible primary recombinant strains (1HR).

[0080] 1.3 Verification of the primary recombinant strain

[0081] Randomly pick multiple monoclonal colonies grown on the BG-G screening plates with a sterile pipette tip and streak them on a new BG-G plate. Dip the remaining bacteria on the pipette tip into 50 μL of sterile water as the PCR verification template, and verify using the verification primers specific for the upstream homologous arm integration and / or the downstream integration specific verification primers, and select the clones with correct primary recombination.

[0082] 1.4 Counter-selection culture and verification of the secondary recombinant strain

[0083] Select the clones with correct primary recombination and streak them on a BG plate containing 2% DOG (2-Deoxy-D-galactose). Incubate the plate at 37 °C, and the monoclonal colonies that grow are the possible secondary recombinant strains (2HR). Randomly pick multiple monoclonal colonies grown on the BG-2% DOG screening plates with a sterile pipette tip and streak them on a new BG plate. Dip the remaining bacteria on the pipette tip into 50 μL of sterile water as the PCR verification template, and verify using the genomic external primers, and select the clones with correct secondary recombination.

[0084] The genomic external primers refer to using the upstream sequence of the upstream homologous arm as the forward primer (excluding the upstream homologous arm itself) and the downstream sequence of the downstream homologous arm as the reverse primer (excluding the downstream homologous arm itself).

[0085] Example 2: Knock out BP2992, pldA and mlaF, and after sonication, the OMV production increases by dozens of times compared with BAA-589

[0086] Construct a triple knockout strain of pldA, mlaF and BP2992, and it is found that when sonicated, the yield of OMV is increased by dozens of times compared with BAA-589.

[0087] Use the homologous recombination method in Example 1 to knock out the BP2992 gene in the Bordetella pertussis BAA-589 strain. Specifically, the plasmid carrying the upstream homologous arm and the downstream homologous arm of the BP2992 gene is electrotransformed into the Bordetella pertussis BAA-589 strain. Through primary homologous recombination and secondary homologous recombination, after sequencing confirmation, BP2992 has been successfully knocked out (the sequencing results are as Figure 2 shown), and the strain BAA-589ΔBP2992 is obtained.

[0088] The nucleotide sequence of BP2992 is shown in SEQ ID NO: 6, the amino acid sequence of the BP2992 protein is shown in SEQ ID NO: 7, the upstream homologous arm sequence used in the gene editing process by the homologous recombination method is shown in SEQ ID NO: 8, and the downstream homologous arm sequence is shown in SEQ ID NO: 9.

[0089] Using the homologous recombination method of Example 1, the pldA gene was knocked out in the strain BAA-589ΔBP2992. Specifically, the plasmid carrying the upstream and downstream homologous arms of the pldA gene was electrotransformed into the Bordetella pertussis BAA-589ΔBP2992 strain. Through a first homologous recombination and a second homologous recombination, it was confirmed by sequencing that pldA had been successfully knocked out (the sequencing results are as Figure 3 shown), and the strain BAA-589ΔBP2992ΔpldA was obtained.

[0090] The nucleotide sequence of the pldA gene is shown in SEQ ID NO: 10, the amino acid sequence of the pldA protein is shown in SEQ ID NO: 11, the upstream homologous arm sequence used in the gene editing process by the homologous recombination method is shown in SEQ ID NO: 12, and the downstream homologous arm sequence is shown in SEQ ID NO: 13.

[0091] Using the homologous recombination method of Example 1, the mlaF gene was knocked out in the strain BAA-589ΔBP2992ΔpldA. Specifically, the plasmid carrying the upstream and downstream homologous arms of the mlaF gene was electrotransformed into the Bordetella pertussis BAA-589ΔBP2992ΔpldA strain. Through a first homologous recombination and a second homologous recombination, it was confirmed by sequencing that mlaF had been successfully knocked out (the sequencing results are as Figure 4 shown), and the strain BAA-589ΔBP2992ΔpldAΔmlaF was obtained.

[0092] The nucleotide sequence of the mlaF gene is shown in SEQ ID NO: 14, the amino acid sequence of the mlaF protein is shown in SEQ ID NO: 15, the upstream homologous arm sequence used in the gene editing process by the homologous recombination method is shown in SEQ ID NO: 16, and the downstream homologous arm sequence is shown in SEQ ID NO: 17.

[0093] After the strain was successfully constructed, the OMV production of the BAA-589ΔBP2992ΔpldAΔmlaF strain was further evaluated under ultrasonic conditions.

[0094] The BAA-589 and BAA-589ΔBP2992ΔpldAΔmlaF strains with activated BG plates were respectively inoculated into shake flasks containing 50 ml of SS medium and cultured overnight on a shaker at 35 °C and 220 rpm. Measure the OD600 of the seed solution, take an appropriate amount of the seed solution and re-inoculate it into a shake flask containing 200 ml of SS medium, control the initial OD600 = 0.4, place the test tube on a shaker at 35 °C and 220 rpm and culture for about 24 h, and collect samples. Measure the OD600 of the fermentation broth, and the results are as Figure 5 shown. The growth of the triple-knockout strain BAA-589ΔBP2992ΔpldAΔmlaF was inferior to that of the wild-type strain BAA-589. Centrifuge 200 ml of the fermentation sample at 4000 rpm for 1 h, and collect the supernatant and precipitate respectively.

[0095] The supernatant of 200 ml of the fermentation broth was used to prepare a sample of naturally secreted OMV. Filter the supernatant using a 0.22 μm filter membrane, then take 140 ml of the filtrate and centrifuge and concentrate it using an ultracentrifuge (WX+ULTRA, Thermo) under the conditions of: 100,000 g, 2 h. After ultracentrifugation, discard the supernatant and collect the precipitate. Add 1 ml of buffer to resuspend the precipitate, and after further filtering with a 0.22 μm filter membrane, it is the OMV sample, denoted as nOMV (natural OMV).

[0096] The precipitate of 200 ml of fermentation broth was used to prepare ultrasonically induced OMV samples. The precipitate was resuspended in 20 ml of buffer (50 mM Tris, 150 mM NaCl, pH = 7.4), pipetted to disperse evenly, and then 10 ml was taken for subsequent experiments. The cell samples were inactivated by heating in a water bath at 56 °C for 30 min. The inactivated samples were ultrasonically treated using an ultrasonic cell disruptor (VCX130, SONICS) under the conditions of: 84.5 W power, running for 5 s, stopping for 5 s, for 5 min (the inventors found in practice that for bacterial solutions with a concentration of 20 - 40 OD / 10 ml, ultrasonic parameters controlled within the range of 65 - 90 W power, running for 3 - 5 s, stopping for 5 - 10 s, for 3 - 7 min of ultrasonic treatment could not only prevent bacteria from lysing but also promote the secretion of OMV from the bacteria). After ultrasonication, the samples were centrifuged at 4000 rpm for 1 h, and the supernatant was filtered through a 0.22 μm filter membrane. Then, a high-speed centrifuge (WX + ULTRA, Thermo) was used to centrifuge and remove larger cell debris in the supernatant under the conditions of: 30000 g, for 30 min. Among them, 7.56 ml of supernatant was taken for the BAA - 589 sample; 6.93 ml of supernatant was taken for the BAA - 589ΔBP2992ΔpldAΔmlaF sample. After ultracentrifugation, the supernatant was transferred and ultracentrifuged again under the conditions of: 100000 g, for 2 h. After ultracentrifugation, the supernatant was discarded and the precipitate was collected. The precipitate was resuspended in 1 ml of buffer and further filtered through a 0.22 μm filter membrane to obtain the OMV sample, denoted as sOMV (spontaneous OMV).

[0097] The protein concentration of OMV was measured using the BCA method, and the results are as Figure 6 shown. From the characterization results, it can be seen that under the above culture conditions, the OMV (nOMV) spontaneously secreted by the BAA - 589ΔBP2992ΔpldAΔmlaF strain is 4 times that of the wild - type strain (1.2 & 0.3). Using ultrasonic treatment, the OMV produced by the strains all increased significantly. Among them, the OMV yield of the wild - type strain increased by 4 times (1.2 & 0.3), that is, sOMV is 4 times that of nOMV; while the OMV yield of the BAA - 589ΔBP2992ΔpldAΔmlaF strain increased by 16 times (19.11 & 1.2), that is, sOMV is 16 times that of nOMV. This result shows that under ultrasonic conditions, compared with spontaneous secretion, the BAA - 589ΔBP2992ΔpldAΔmlaF strain has a greater multiple of increased production than the wild - type strain. The sOMV of the BAA - 589ΔBP2992ΔpldAΔmlaF strain is 16 times that of the wild - type strain sOMV (19.11 & 1.2). This result indicates that under ultrasonic conditions, the increase in OMV production of the triple - knockout strain BAA - 589ΔBP2992ΔpldAΔmlaF is extremely significant.

[0098] The sOMV particle concentration was measured using a nanoparticle tracking analyzer (Malvern, NanoSight Pro), and the results are as Figure 7 shown. From the characterization results, it can be seen that under ultrasonic conditions, the sOMV production of the BAA-589ΔBP2992ΔpldAΔmlaF strain is 23 times that of the wild-type strain sOMV.

[0099] The sOMV particle size was measured using a nano particle size and zeta potential analyzer (Malvern, Zetasizer Pro), and the results are as Figure 8 shown. The dispersity of both samples is small, indicating that the sOMV purified by the ultrasonic method has a high quality.

[0100] From the characterization results, it can be judged that under ultrasonic conditions, the OMV produced by the BAA-589ΔBP2992ΔpldAΔmlaF strain is dozens of times that of the wild type.

[0101] Example 3: Knock out pldA and mlaF, and the OMV production increases by 3-6 times under ultrasonic treatment compared with BAA-589

[0102] Using the homologous recombination method of Example 1 and similar treatments of Example 2, the strain BAA-589ΔpldA was obtained, and then the double-knockout strain 589ΔpldAΔmlaF was further obtained.

[0103] After the strain construction was successful, the growth status of the BAA-589ΔpldAΔmlaF strain and the production of OMV under natural secretion and ultrasonic conditions were further evaluated. According to the culture and detection methods in Example 2, as Figure 9 shown, the growth of BAA-589ΔpldAΔmlaF is similar to that of BAA-589ΔBP2992ΔpldAΔmlaF and is inferior to that of the wild-type strain BAA-589.

[0104] The protein concentration of OMV was measured using the BCA method, and the results are as Figure 10As shown, under the above culture conditions, the naturally secreted OMV (nOMV) of the BAA-589ΔpldAΔmlaF strain is 5 times that of the wild-type strain (1.4 & 0.3). Using sonication, the OMV produced by the strains all increased significantly. Among them, the OMV yield of the wild-type strain increased by 4 times (1.2 & 0.3), that is, sOMV is 4 times that of nOMV; while the OMV yield of the BAA-589ΔpldAΔmlaF strain increased by 3 times (3.84 & 1.4), that is, sOMV is 3 times that of nOMV. This result shows that under sonication conditions, compared with natural secretion, the amplification multiples of the BAA-589ΔpldAΔmlaF strain and the wild-type strain are comparable. The sOMV of the BAA-589ΔpldAΔmlaF strain is 3 times that of the wild-type strain sOMV (3.84 & 1.2). This result indicates that under sonication conditions, the OMV production increase trend of the double-knockout strain BAA-589ΔpldAΔmlaF is close to that of the wild-type strain. Therefore, whether it is sonication or natural secretion, the OMV produced by the BAA-589ΔpldAΔmlaF strain is 3-5 times that of the wild-type strain.

[0105] The concentration of sOMV particles was measured using a nanoparticle tracking analyzer (Malvern, NanoSight Pro), and the results are as Figure 11 shown. From the characterization results, it can be seen that under sonication conditions, the sOMV yield of the BAA-589ΔpldAΔmlaF strain is 6 times that of the wild-type strain sOMV.

[0106] The particle size of sOMV was measured using a nanoparticle size and zeta potential analyzer (Malvern, Zetasizer Pro), and the results are as Figure 12 shown. The dispersity of both samples is small, indicating again that the sOMV purified by sonication has a high quality.

[0107] From this, it can be known that during natural secretion, the nOMV yields of the BAA-589ΔpldAΔmlaF strain and the BAA-589ΔBP2992ΔpldAΔmlaF strain are 5-4 times that of the wild-type strain. During sonication, the sOMV yields of the strains all increased. Among them, the increase in the BAA-589ΔBP2992ΔpldAΔmlaF strain was particularly significant, and the final yield reached dozens of times that of the wild-type strain.

Claims

1. A modified Bordetella pertussis strain, characterized in that The Bordetella pertussis strain is a strain of Bordetella pertussis BAA-589 that does not express BP2992 protein or expresses inactive BP2992 protein, does not express pldA protein or expresses inactive pldA protein, and does not express mlaF protein or expresses inactive mlaF protein.

2. The Bordetella pertussis strain according to claim 1, characterized in that The Bordetella pertussis strain comprises BP2992, pldA and mlaF gene mutations.

3. The Bordetella pertussis strain according to claim 2, characterized in that The BP2992 gene encodes the amino acid sequence shown in SEQ ID NO: 7 or its nucleotide sequence is shown in SEQ ID NO:

6.

4. The Bordetella pertussis strain according to claim 3, characterized in that The pldA gene encodes the amino acid sequence shown in SEQ ID NO: 11 or its nucleotide sequence is shown in SEQ ID NO: 10; and / or, the mlaF gene encodes the amino acid sequence shown in SEQ ID NO: 15 or its nucleotide sequence is shown in SEQ ID NO:

14.

5. A method for producing a modified Bordetella pertussis strain, the method comprising: Introducing mutations into the BP2992 gene, the pldA gene, and the mlaF gene in the Bordetella pertussis strain to obtain a modified Bordetella pertussis strain in which the BP2992 gene, the pldA gene, and the mlaF gene are all mutated; Wherein, the Bordetella pertussis strain is Bordetella pertussis strain BAA-589.

6. A method for preparing pertussis outer membrane vesicles, characterized in that: The method comprises using ultrasound to treat the Bordetella pertussis strain according to any one of claims 1-4.

7. The method according to claim 6, characterized in that The ultrasonic treatment does not lyse the bacteria of the Bordetella pertussis strain, but promotes the secretion of pertussis outer membrane vesicles of the bacteria.

8. The method according to claim 6 or 7, characterized in that The method comprises the following steps: a) culturing the Bordetella pertussis strain according to any one of claims 1 to 4; b) using ultrasound to treat the strain obtained in step a) to produce pertussis outer membrane vesicles.

9. Use of the Bordetella pertussis strain according to any one of claims 1 to 4 in the preparation of pertussis outer membrane vesicles.

10. A composition comprising at least two of the following: (1) The Bordetella pertussis strain according to any one of claims 1 to 4; (2) Adjuvant and / or pharmaceutically acceptable carrier.

11. Use of the Bordetella pertussis strain according to any one of claims 1 to 4 or the composition according to claim 10 in the preparation of a medicament or vaccine for preventing and / or treating Bordetella pertussis infection.

Citation Information

Patent Citations

  • Seamless gene editing method for bordetella pertussis

    CN117947054A

  • Modified bordetella pertussis strains

    CN118853525A

  • Pertussis antigens and use thereof in vaccination

    US20070116711A1

  • Hyperblebbing bacterial strains and use thereof for production of vaccines

    WO2002062378A2

  • Bordetella outer membrane vesicles

    WO2022019769A1

Cited By

  • Attenuated bordetella pertussis recombinant strain as well as construction method and application thereof

    CN120624499A

  • High-efficiency traceless gene editing method for bordetella pertussis, vector and application thereof

    CN121538244A

  • Bordetella pertussis engineering strain as well as preparation method and application thereof

    CN121653033A

  • Bordetella pertussis strain with increased outer membrane vesicle yield

    WO2026067896A3